Innova Captab Peer Comparison

Snapshot Summary

Innova Captab Ltd. shows moderate growth and profitability metrics relative to its peers in the Pharmaceuticals & Drugs sector. While it has a reasonable debt level, its high PE ratio suggests it may be overvalued compared to its profitability. Companies like Cipla Ltd. and Mankind Pharma Ltd. demonstrate strong performance, indicating potential value picks for investors.

• Innova Captab Ltd. has a low revenue growth rate YoY (0%) but a robust 3-Year growth (38.09%).
• Cipla Ltd. offers the lowest PE ratio (23.73) and strong profitability metrics, indicating it is a value pick.
• Divi's Laboratories Ltd. has the highest PE (73.20) and low revenue growth, marking it as overvalued.
• Mankind Pharma Ltd. exhibits impressive revenue growth (18.12% YoY), making it a strong contender for growth investment.

• Cipla Ltd.: Lowest PE ratio (23.73) and strong profitability (ROE 16.63%) make it a value pick.
• Mankind Pharma Ltd.: Highest YoY revenue growth (18.12%) with strong profitability (ROE 23.15%).

Stocks	CMP	Market Cap	P/E	ROCE (%)	Debt/Equity
INNOVACAP	₹929.30	₹5,317.91Cr	59.44	19.06%	0.29
SUNPHARMA	₹1,563.35	₹3,75,099.26Cr	87.59	17.60%	0.04
DIVISLAB	₹6,091.05	₹1,61,698.50Cr	73.20	16.46%	-
CIPLA	₹1,587.60	₹1,28,217.27Cr	23.73	22.77%	0.01
TORNTPHARM	₹3,581.55	₹1,21,215.77Cr	61.53	24.28%	0.57
DRREDDY	₹1,280.30	₹1,06,835.27Cr	15.50	26.86%	0.07
MANKIND	₹2,518.95	₹1,03,926.59Cr	55.18	28.38%	0.02

Explore

Watchlists

Command Palette

Innova Captab Peer Comparison

Snapshot Summary